SeaStar Medical Reports Strong Enrollment Progress In Pivotal Adult AKI Trial With 46 Total Subjects Enrolled; Trial Evaluates Safety And Efficacy Of Selective Cytopheretic Device For Acute Kidney Injury Patients In ICU
SeaStar Medical Reports Strong Enrollment Progress In Pivotal Adult AKI Trial With 46 Total Subjects Enrolled; Trial Evaluates Safety And Efficacy Of Selective Cytopheretic Device For Acute Kidney Injury Patients In ICU
SeaStar醫療報告在重要的成人AKI試驗中取得了強勁的招募進展，共有46名受試者入組；試驗評估了用於重症監護病房急性腎損傷患者的選擇性細胞吸附裝置的安全性和有效性
SeaStar Medical Reports Strong Enrollment Progress In Pivotal Adult AKI Trial With 46 Total Subjects Enrolled; Trial Evaluates Safety And Efficacy Of Selective Cytopheretic Device For Acute Kidney Injury Patients In ICU
SeaStar醫療報告在重要的成人AKI試驗中取得了強勁的招募進展，共有46名受試者入組；試驗評估了用於重症監護病房急性腎損傷患者的選擇性細胞吸附裝置的安全性和有效性
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。